| Drug General Information |
| Drug ID |
D0L3RY
|
| Former ID |
DNC007404
|
| Drug Name |
3-methoxy-N-(4-methylthiazol-2-yl)benzamide
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C12H12N2O2S
|
| Canonical SMILES |
CC1=CSC(=N1)NC(=O)C2=CC(=CC=C2)OC
|
| InChI |
1S/C12H12N2O2S/c1-8-7-17-12(13-8)14-11(15)9-4-3-5-10(6-9)16-2/h3-7H,1-2H3,(H,13,14,15)
|
| InChIKey |
PAGPVSQZNPBQLP-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Metabotropic glutamate receptor 5 |
Target Info |
Inhibitor |
[1]
|
|---|
| mRNA of human 5-lipoxygenase |
Target Info |
Inhibitor |
[2]
|
|
BioCyc Pathway
|
Aspirin-triggered lipoxin biosynthesis
|
|
Resolvin D biosynthesis
|
|
Leukotriene biosynthesis
|
|
Lipoxin biosynthesis
|
|
Aspirin triggered resolvin D biosynthesis
|
|
Aspirin triggered resolvin E biosynthesis
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Long-term potentiation
|
|
Retrograde endocannabinoid signaling
|
|
Glutamatergic synapse
|
|
Huntington's diseasehsa00590:Arachidonic acid metabolism
|
|
Metabolic pathways
|
|
Serotonergic synapse
|
|
Ovarian steroidogenesis
|
|
Toxoplasmosis
|
|
NetPath Pathway
|
IL4 Signaling Pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Metabotropic glutamate receptor group III pathway
|
|
Metabotropic glutamate receptor group I pathway
|
|
Endogenous cannabinoid signaling
|
|
PathWhiz Pathway
|
Arachidonic Acid Metabolism
|
|
Reactome
|
G alpha (q) signalling events
|
|
Class C/3 (Metabotropic glutamate/pheromone receptors)
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
GPCRs, Class C Metabotropic glutamate, pheromone
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP2650:Arachidonic acid metabolism
|
|
Eicosanoid Synthesis
|
|
Selenium Micronutrient Network
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5. Epub 2006 May 5.Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. |
|---|
| REF 2 | J Med Chem. 2007 May 31;50(11):2640-6. Epub 2007 Apr 27.Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. |
|---|
